Caspase Cleaved BID Targets Mitochondria and Is Required for Cytochrome c Release, while BCL-XL Prevents This Release but Not Tumor Necrosis Factor-R1/Fas Death*
- Atan Gross‡,
- Xiao-Ming Yin,
- Kun Wang,
- Michael C. Wei,
- Jennifer Jockel,
- Curt Milliman,
- Hediye Erdjument-Bromage§,
- Paul Tempst§ and
- Stanley J. Korsmeyer¶
- From the Howard Hughes Medical Institute, Departments of Medicine and Pathology, Washington University School of Medicine, St. Louis, Missouri 63110 and the §Memorial Sloan-Kettering Cancer Center, New York, New York 10021
Abstract
“BH3 domain only” members of the BCL-2 family including the pro-apoptotic molecule BID represent candidates to connect with proximal signal transduction. Tumor necrosis factor α (TNFα) treatment induced a caspase-mediated cleavage of cytosolic, inactive p22 BID at internal Asp sites to yield a major p15 and minor p13 and p11 fragments. p15 BID translocates to mitochondria as an integral membrane protein. p15 BID within cytosol targeted normal mitochondria and released cytochrome c. Immunodepletion of p15 BID prevents cytochrome c release. In vivo, anti-Fas Ab results in the appearance of p15 BID in the cytosol of hepatocytes which translocates to mitochondria where it releases cytochrome c. Addition of activated caspase-8 to normal cytosol generates p15 BID which is also required in this system for release of cytochrome c. In the presence of BCL-XL/BCL-2, TNFα still induced BID cleavage and p15 BID became an integral mitochondrial membrane protein. However, BCL-XL/BCL-2 prevented the release of cytochromec, yet other aspects of mitochondrial dysfunction still transpired and cells died nonetheless. Thus, while BID appears to be required for the release of cytochrome c in the TNF death pathway, the release of cytochrome c may not be required for cell death.
Footnotes
-
↵* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
↵‡ Supported by a fellowship from European Moleculary Biology Organization.
-
↵¶ To whom correspondence should be addressed: Smith 758, Dana-Farber Cancer Institute, Harvard Medical School, 1 Jimmy Fund Way, Boston, MA 02115. Tel.: 617-632-6404; Fax: 617-632-6401; E-mail:stanley_korsmeyer{at}dfci.harvard.edu.
- TNF
- tumor necrosis factor
- CHX
- cycloheximide
- ROS
- reactive oxygen species
- PAGE
- polyacrylamide gel electrophoresis
- HM
- heavy membrane
- LM
- light membrane
- Ab
- antibody
- rBID
- recombinant BID
- DiOC6((3)
- 3,3′-dihexyloxacarbocynine iodide.
- Received September 30, 1998.
- Revision received October 30, 1998.
- The American Society for Biochemistry and Molecular Biology, Inc.











